Belviq enters Asian arena as Ildong gains Korean rights
This article was originally published in Scrip
Executive Summary
As originator Arena Pharmaceuticals awaits formal classification of Belviq (lorcaserin) as a controlled substance in the US, it has moved ahead with its first Asian licensing deal for the obesity drug.